Glenmark Pharmaceuticals Reports Significant Q4 Growth with Strategic Developments
Glenmark Pharma posts robust Q4 performance

Image: Business Standard
Glenmark Pharmaceuticals achieved a remarkable Q4 FY26, with net profit soaring to ₹301.41 crore, a 64-fold increase from the previous year. Revenue rose 16.8% YoY to ₹3,760.28 crore, driven by strong performances across various markets. The company also announced a strategic transfer of nebulizer brands to Glenmark Healthcare for ₹223 crore.
- 01Glenmark's consolidated net profit for Q4 FY26 reached ₹301.41 crore, up from ₹4.65 crore in Q4 FY25.
- 02Revenue from operations increased by 16.8% YoY to ₹3,760.28 crore in Q4 FY26.
- 03The company's profit before tax surged to ₹387.77 crore from ₹7.97 crore year-on-year.
- 04Revenue from North America rose 29.4% to ₹924.8 crore, while Europe saw a 21.4% increase to ₹890.7 crore.
- 05The board approved the transfer of nebulizer brands to Glenmark Healthcare for ₹223 crore, expected to be finalized by June 30, 2026.
Advertisement
In-Article Ad
Glenmark Pharmaceuticals reported a substantial increase in its financial performance for Q4 FY26, with consolidated net profit skyrocketing to ₹301.41 crore, a remarkable growth from ₹4.65 crore in Q4 FY25. Revenue from operations also saw a 16.8% year-on-year increase, reaching ₹3,760.28 crore. The profit before tax (PBT) experienced a significant rise to ₹387.77 crore, compared to ₹7.97 crore in the same quarter last year. The company's performance was bolstered by a 29.4% increase in revenue from North America, totaling ₹924.8 crore, and a 21.4% rise in Europe, reaching ₹890.7 crore. For the fiscal year ending March 31, 2026, Glenmark's net profit grew by 30.06% to ₹1,361.85 crore. Chairman Glenn Saldanha highlighted the year as a pivotal one for the company, emphasizing the successful launch of key generic respiratory products and the strategic partnership with AbbVie. Additionally, the board approved the transfer of nebulizer brands to Glenmark Healthcare for ₹223 crore, expected to be completed by June 30, 2026.
Advertisement
In-Article Ad
Glenmark's strong financial performance could lead to increased investor confidence and potential job growth within the company.
Advertisement
In-Article Ad
Reader Poll
What do you think of Glenmark's financial performance in Q4 FY26?
Connecting to poll...
Read the original article
Visit the source for the complete story.

&w=1200&q=75)


